LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that its proprietary method for manufacturing ICT-107, its lead dendritic cell (DC) based vaccine for the treatment of glioblastoma multiforme (GBM), has demonstrated meaningfully enhanced efficiency, consistency and convenience, compared to other methods for producing DC-based immunotherapies.
